These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6162036)

  • 1. Studies of A, B or O (H) surface antigen specificity: carcinoma in situ and non-malignant lesions of the bladder.
    Emmott RC; Droller MJ; Javadpour N
    J Urol; 1981 Jan; 125(1):32-5. PubMed ID: 6162036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further studies on specificity of red cell adherence test: nonmalignant bladder lesions.
    Ghazizadeh M; Kagawa S; Yoneda F; Imagawa A; Kurokawa K
    Urology; 1985 Jan; 25(1):85-7. PubMed ID: 3966294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urothelium and the Specific Red Cell Adherence Test.
    Gunter PA; De Abela-Borg J; Pugh RC
    Br J Urol; 1983 Feb; 55(1):10-6. PubMed ID: 6824850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of blood-group-related antigens in carcinoma in situ of the urinary bladder.
    Coon JS; McCall A; Miller AW; Farrow GM; Weinstein RS
    Cancer; 1985 Aug; 56(4):797-804. PubMed ID: 4016671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The specific erythrocyte adherence method in the study of ABH antigens on normal and neoplastic bladder epithelium].
    Ongaro G; Issi M; Gallo T; Garbeglio A; Ranieri A; Dalla Palma P
    Quad Sclavo Diagn; 1983 Jun; 19(2):242-61. PubMed ID: 6676774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship of ABH(O) blood group antigen expression in intraepithelial dysplastic lesions to clinicopathologic properties of associated transitional cell carcinoma of the bladder.
    Yamada T; Fukui I; Kobayashi T; Sekine H; Yokogawa M; Yamada T; Oshima H
    Cancer; 1991 Mar; 67(6):1661-6. PubMed ID: 2001555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of ABH antigens and CEA for the prognosis of urothelial tumors].
    Hofstädter F; Jakse G
    Wien Klin Wochenschr; 1982 Jul; 94(14):366-8. PubMed ID: 7147976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell surface A, B, or O(H) blood group antigens as an indicator of malignant potential in stage A bladder carcinoma.
    Newman AJ; Carlton CE; Johnson S
    J Urol; 1980 Jul; 124(1):27-9. PubMed ID: 7411715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood group isoantigen deletion in carcinoma in situ of the urinary bladder.
    Weinstein RS; Alroy J; Farrow GM; Miller AW; Davidsohn I
    Cancer; 1979 Feb; 43(2):661-8. PubMed ID: 421187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cell surface antigens of bladder washing specimens in patients with bladder tumors, a new approach.
    Sadoughi N; Rubenstone A; Mlsna J; Davidsohn I
    J Urol; 1980 Jan; 123(1):19-21. PubMed ID: 6985978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of specific red-cell adherence and immunoperoxidase staining techniques for ABO(H) blood-group cell-surface antigens on superficial transitional cell carcinoma of the bladder.
    Boileau MA; Cowles RS; Schmidt KL; Schmidt WA
    J Surg Oncol; 1985 Oct; 30(2):72-9. PubMed ID: 3908825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABH antigenicity of in situ carcinoma of the urinary bladder during intracavity treatment with doxorubicin hydrochloride.
    Jakse G; Hofstädter F
    Urol Res; 1981; 9(3):153-6. PubMed ID: 7257030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The specific red cell adherence test in transitional cell carcinoma of the bladder before and after radiotherapy in patients with blood group A.
    Wolk FN; Bishop MC
    J Urol; 1983 Jul; 130(1):71-3. PubMed ID: 6345808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of action of intravesical treatment. Effect on the ABH surface antigens of urothelial cells.
    Jakse G; Hofstädter F
    Cancer Chemother Pharmacol; 1983; 11 Suppl():S74-8. PubMed ID: 6640839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of ABO(H) isoantigen expression in bladder tumors.
    Srinivas V; Orihuela E; Lloyd KO; Old LJ; Whitmore WF
    J Urol; 1985 Jan; 133(1):25-8. PubMed ID: 3964875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occurrence of ABO group antigens in bladder carcinoma.
    Schlesinger D; Stolarczyk J; Błaszczuk J
    Arch Immunol Ther Exp (Warsz); 1986; 34(2):171-4. PubMed ID: 2431666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic indicators of prognosis in bladder cancer: the importance of cell surface antigens.
    Richie JP; Blute RD; Waisman J
    J Urol; 1980 Jan; 123(1):22-4. PubMed ID: 6985979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of the demonstration of A, B, H surface antigens in bladder tumors by a simple immunofluorescence technique.
    Hammou JC; Fella C; Vacant J; Maiolini R; Masseyeff R
    J Urol; 1982 Dec; 128(6):1183-7. PubMed ID: 6759688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [ABH isoantigen of superficial urothelial tumor and carcinoma in situ of the bladder by the avidin-biotin peroxidase complex(ABC) method].
    Sasaki K
    Nihon Hinyokika Gakkai Zasshi; 1983 Aug; 74(8):1326-38. PubMed ID: 6374223
    [No Abstract]   [Full Text] [Related]  

  • 20. [The study of ABH isoantigen and T (Thomsen-Friedenreich) antigen of superficial urothelial tumor].
    Sasaki K
    Hokkaido Igaku Zasshi; 1984 Nov; 59(6):679-89. PubMed ID: 6530208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.